Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01642550 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

A Phase 2 study, sponsored by Motus Therapeutics.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01642550 is a Phase 2 study that has completed, run by Motus Therapeutics. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01642550, a Phase 2 study, has completed, sponsored by Motus Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to determine if administration of RM-131 is effective in improving appetite and gastrointestinal symptoms leading to the recovery of patients with anorexia nervosa in the outpatient setting.

Interventions

  • DRUG Placebo
  • DRUG RM-131

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2012-11
Est. Completion 2015-03
Phase Phase 2

Sponsor

Motus Therapeutics

7 total trials

What the Registry Record Tells You About NCT01642550

The ClinicalTrials.gov registry entry for NCT01642550 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Motus Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01642550 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01642550 about?

NCT01642550 is a clinical study titled "Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa". The purpose of this study is to determine if administration of RM-131 is effective in improving appetite and gastrointestinal symptoms leading to the recovery of patients with anorexia nervosa in the outpatient setting.

What is the current status of trial NCT01642550?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-11. Estimated completion is 2015-03.

What interventions are being tested in trial NCT01642550?

The interventions under investigation include: Placebo (DRUG), RM-131 (DRUG).

Who is sponsoring clinical trial NCT01642550?

This trial is sponsored by Motus Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.